Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Human Resources Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,961 |
Reported balance
After 2026-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-11 · Grant · Acquired 3,587 · Balance 25,961 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 24,025 |
Reported balance
After 2026-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-11 · Tax withholding · Disposed 1,936 · Balance 24,025 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. F3: 21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
F3: 21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2024 Filed Jul 3, 2024 01:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 10,000 | $61.82 | $618,200.00 |
DisclosureSEC source: 0000914475-24-000166 · wk-form4_1719970585.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 226 shares purchased on February 29, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 5,604 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · derivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,604 Underlying: Common Stock · 5,604 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 28,161 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · derivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,161 Underlying: Common Stock · 28,161 shares Expires 2034-02-13 F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 796 | $133.04 | $105,902.15 |
DisclosureSEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,976 F1 · kind: Sale of 796 shares of common stock issued upon vesting of 1,509 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (713) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 629 | $136.78 | $86,034.62 |
DisclosureSEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 4 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,263 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 700 | $134.23 | $93,960.86 |
DisclosureSEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,892 F4 · kind: Sale of 700 shares of common stock issued upon vesting of 1,329 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (629) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 575 | $141.96 | $81,627.00 |
DisclosureSEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,263 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 640 | $142.17 | $90,989.76 |
DisclosureSEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,838 F1 · kind: Sale of 640 shares of common stock issued upon vesting of 1,215 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (575) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.05 to $143.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 824 | $141.94 | $116,958.56 |
DisclosureSEC source: 0000914475-24-000025 · wk-form4_1706919106.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,263 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 916 | $140.70 | $128,882.94 |
DisclosureSEC source: 0000914475-24-000025 · wk-form4_1706919106.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,087 F1 · kind: Sale of 916 shares of common stock issued upon vesting of 1,740 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (824) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.74 to $142.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 21:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 10,000 | $61.82 Strike: $61.82 | $618,200.00 |
DisclosureSEC source: 0001209191-23-059768 · doc4.xml · derivative · entry 6 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,532 Underlying: Common Stock · 10,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Option granted October 02, 2017 of which 1/4th of the shares underlying the option becomes vested and exercisable on October 02, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 21:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 14,000 | $81.05 Strike: $81.05 | $1,134,700.00 |
DisclosureSEC source: 0001209191-23-059768 · doc4.xml · derivative · entry 5 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,129 Underlying: Common Stock · 14,000 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option granted February 07, 2019 and vested monthly over four years. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 21:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 10,000 | $126.79 | $1,267,945.00 |
DisclosureSEC source: 0001209191-23-059768 · doc4.xml · nonDerivative · entry 4 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,263 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $128.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 21:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 10,000 | $61.82 | $618,200.00 |
DisclosureSEC source: 0001209191-23-059768 · doc4.xml · nonDerivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 21:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 14,000 | $129.99 | $1,819,862.80 |
DisclosureSEC source: 0001209191-23-059768 · doc4.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,263 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.95 to $130.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 21:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 14,000 | $81.05 | $1,134,700.00 |
DisclosureSEC source: 0001209191-23-059768 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 824 | $110.93 | $91,406.32 |
DisclosureSEC source: 0001209191-23-048381 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,263 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| August 21, 2023 Filed Aug 24, 2023 00:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,132 | $107.41 | $228,990.66 |
DisclosureSEC source: 0001209191-23-047133 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,087 F1 · kind: Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 01, 2023 Filed May 3, 2023 21:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 11,397 | $103.89 | $1,184,049.15 |
DisclosureSEC source: 0001209191-23-027089 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,169 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.82 to $104.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 20:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 100 | $103.82 | $10,382.00 |
DisclosureSEC source: 0001209191-23-025862 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,561 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · balance_after: Includes an aggregate of 237 shares purchased on February 28, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 6,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009883 · doc4.xml · derivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,038 Underlying: Common Stock · 6,038 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 37,523 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0001209191-23-009883 · doc4.xml · derivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,523 Underlying: Common Stock · 37,523 shares Expires 2033-02-13 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 00:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 628 | $103.69 | $65,117.32 |
DisclosureSEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 7 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,424 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 00:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 700 | $103.95 | $72,765.98 |
DisclosureSEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 6 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,052 F9 · kind: Sale of 700 shares of common stock issued upon vesting of 1,328 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (628) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F10 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $105.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 00:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 822 | $104.03 | $85,512.66 |
DisclosureSEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 5 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,424 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 00:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 12,801 | $102.41 | $1,310,915.85 |
DisclosureSEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 4 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,246 F6 · kind: Sale of 12,801 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,497) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan F7 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.03 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 00:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 913 | $102.25 | $93,350.32 |
DisclosureSEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,749 F4 · kind: Sale of 913 shares of common stock issued upon vesting of 1,736 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (823) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.87 to $103.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 00:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 575 | $104.28 | $59,961.00 |
DisclosureSEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,926 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 00:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 640 | $105.47 | $67,498.18 |
DisclosureSEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,501 F1 · kind: Sale of 640 shares of common stock issued upon vesting of 1,215 restricted stock units on February 6, 2022 to cover payroll and withholding taxes, with the balance of the shares (575) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.05 to $106.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 916 | $108.48 | $99,367.68 |
DisclosureSEC source: 0001209191-23-006267 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,926 F1 · kind: Sale of 916 shares of common stock issued upon vesting of 1,740 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (824) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,592 | $81.05 Strike: $81.05 | $453,231.60 |
DisclosureSEC source: 0001209191-22-056435 · doc4.xml · derivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,129 Underlying: Common Stock · 5,592 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 07, 2019 and vested monthly over four years. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,592 | $124.99 | $698,949.11 |
DisclosureSEC source: 0001209191-22-056435 · doc4.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,102 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.95 to $125.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,592 | $81.05 | $453,231.60 |
DisclosureSEC source: 0001209191-22-056435 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 7,264 | $81.05 Strike: $81.05 | $588,747.20 |
DisclosureSEC source: 0001209191-22-055819 · doc4.xml · derivative · entry 6 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,721 Underlying: Common Stock · 7,264 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 07, 2019 and vested monthly over four years. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 7,264 | $125.00 | $908,034.14 |
DisclosureSEC source: 0001209191-22-055819 · doc4.xml · nonDerivative · entry 4 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,102 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.95 to $125.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 7,264 | $81.05 | $588,747.20 |
DisclosureSEC source: 0001209191-22-055819 · doc4.xml · nonDerivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,144 | $81.05 Strike: $81.05 | $92,721.20 |
DisclosureSEC source: 0001209191-22-055819 · doc4.xml · derivative · entry 5 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,985 Underlying: Common Stock · 1,144 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 07, 2019 and vested monthly over four years. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,144 | $124.97 | $142,962.82 |
DisclosureSEC source: 0001209191-22-055819 · doc4.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,102 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.95 to $125.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,144 | $81.05 | $92,721.20 |
DisclosureSEC source: 0001209191-22-055819 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 22:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,816 | $100.00 | $181,600.00 |
DisclosureSEC source: 0001209191-22-045082 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,102 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 20:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 754 | $100.00 | $75,400.00 |
DisclosureSEC source: 0001209191-22-039808 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,918 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · balance_after: Includes an aggregate of 261 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 23:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 700 | $79.56 | $55,689.13 |
DisclosureSEC source: 0001209191-22-008205 · doc4.xml · nonDerivative · entry 4 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,411 F7 · kind: Sale of 700 shares of common stock issued upon vesting of 1,328 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (628) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.10 to $79.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 640 | $80.63 | $51,600.19 |
DisclosureSEC source: 0001209191-22-008205 · doc4.xml · nonDerivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,783 F5 · kind: Sale of 640 shares of common stock issued upon vesting of 1,215 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (575) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.76 to $81.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 913 | $80.73 | $73,706.76 |
DisclosureSEC source: 0001209191-22-008205 · doc4.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,208 F3 · kind: Sale of 913 shares of common stock issued upon vesting of 1,735 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (822) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.79 to $81.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 605 | $80.55 | $48,731.24 |
DisclosureSEC source: 0001209191-22-008205 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,386 F1 · kind: Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.78 to $81.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 6,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006592 · doc4.xml · derivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,961 Underlying: Common Stock · 6,961 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 47,401 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001209191-22-006592 · doc4.xml · derivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,401 Underlying: Common Stock · 47,401 shares Expires 2032-01-31 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 987 | $101.73 | $100,407.51 |
DisclosureSEC source: 0001209191-21-059839 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,841 F1 · kind: Sale of 987 shares of common stock issued upon vesting of 1,875 restricted stock units on October 4, 2021 to cover payroll and withholding taxes, with the balance of the shares (888) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · balance_after: Includes 216 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 26, 2021. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 5,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009125 · doc4.xml · derivative · entry 5 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,314 Underlying: Common Stock · 5,314 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 31,880 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009125 · doc4.xml · derivative · entry 4 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,880 Underlying: Common Stock · 31,880 shares Expires 2031-02-08 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.